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Accumulating evidence suggests that the efficacy of ACT
in melanoma is mediated by T cells that target somatic
mutations expressed by the patients’ tumors. Moreover, in
one patient with metastatic epithelial (bile duct) cancer,
we recently identified tumor-infiltrating Th1 cells that spe-
cifically recognized a mutation in ERBB2IP expressed by
the patient’s tumors and observed tumor regression after
adoptive transfer of a highly enriched population of ERB-
B2IP mutation-specific Th1 cells. Thus, we hypothesize
that mutation-specific T cells may be frequently elicited in
patients with metastatic gastrointestinal (GI) cancers and
may be harnessed for ACT. To test this, we first per-
formed whole-exome sequencing on metastatic lesions
from GI cancer patients to identify the mutations. Next,
we generated mingene constructs that encoded each
mutation and transfected these minigenes into autologous
antigen presenting cells (APCs) to allow for the processing
and presentation of all the mutations expressed by the
tumor. These APCs were then co-cultured with tumor
infiltrating lymphocytes (TIL) and T cell reactivity against
the mutations was determined by IFN-g ELISPOT and
4-1BB and OX40 upregulation by flow cytometry. In one
patient with colon cancer, 119 mutations were evaluated
for mutation reactivity. Several, but not all, TIL cultures
were found to contain highly variable proportions of
CD8+ T cells that specifically recognized a mutation in
CASP8 (67 F®V). Intriguingly, upon further expansion
in vitro, these mutation-reactive CD8+ T cells were mark-
edly outgrown by other cells in culture. In another patient
with rectal cancer, 155 mutations were evaluated for
mutation reactivity. We found at least 3 different mutation
reactivities, two comprising CD8+ T cell responses and
one CD4+ T cell response. In a third patient (cholangio-
carcinoma), we did not detect T cells reactive against
38 mutations tested. For this patient, the “mutation call”
threshold has been lowered and an additional 125 putative
mutations will be evaluated. Thus, our preliminary data
suggests that the ability of the human immune system to
mount a T cell response against somatic mutations in
metastatic GI cancers may not be a rare event. Current
efforts are focused on evaluating more patients for
mutation-specific T cell responses and on developing
methods to enrich mutation-specific T cells or T cell
receptors for therapy, which may provide a path to extend
cell transfer immunotherapy to almost all common solid
cancers.
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